The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics.

MLA

Kristensen, Anna Meta Dyrvig, et al. “The Danish-Norwegian Randomized Trial on Beta-Blocker Therapy after Myocardial Infarction: Design, Rationale, and Baseline Characteristics.” European Heart Journal. Cardiovascular Pharmacotherapy, vol. 10, no. 3, May 2024, pp. 175–83. EBSCOhost, https://doi.org/10.1093/ehjcvp/pvad093.

APA

Kristensen, A. M. D., Munkhaugen, J., Halvorsen, S., Olsen, M. H., Bakken, A., Sehested, T. S. G., Ruddox, V., Lange, T., Fagerland, M. W., Torp-Pedersen, C., Prescott, E., & Atar, D. (2024). The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics. European Heart Journal. Cardiovascular Pharmacotherapy, 10(3), 175–183. https://doi.org/10.1093/ehjcvp/pvad093

Chicago

Kristensen, Anna Meta Dyrvig, John Munkhaugen, Sigrun Halvorsen, Michael Hecht Olsen, Arnhild Bakken, Thomas Steen Gyldenstierne Sehested, Vidar Ruddox, et al. 2024. “The Danish-Norwegian Randomized Trial on Beta-Blocker Therapy after Myocardial Infarction: Design, Rationale, and Baseline Characteristics.” European Heart Journal. Cardiovascular Pharmacotherapy 10 (3): 175–83. doi:10.1093/ehjcvp/pvad093.